Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Kala Pharmaceuticals, Inc. KALA
$16.43
-$1.21 (-7.38%)
На 18:00, 12 мая 2023
+1 117.29%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
35425995.00000000
-
week52high
56.72
-
week52low
3.54
-
Revenue
3892000
-
P/E TTM
-36
-
Beta
-1.56608900
-
EPS
-28.96000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 15 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 24 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 17 мая 2022 г. |
| Northland Capital Markets | Outperform | Outperform | 30 мар 2022 г. |
| JP Morgan | Underweight | Neutral | 30 мар 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Iwicki Mark T | D | 45966 | 198 | 04 янв 2023 г. |
| Iwicki Mark T | A | 46164 | 41700 | 04 янв 2023 г. |
| Bazemore Todd | D | 14835 | 62 | 04 янв 2023 г. |
| Bazemore Todd | A | 14897 | 12800 | 04 янв 2023 г. |
| Brazzell Romulus K | D | 18536 | 73 | 04 янв 2023 г. |
| Brazzell Romulus K | A | 18609 | 12800 | 04 янв 2023 г. |
| Reumuth Mary | D | 11883 | 60 | 04 янв 2023 г. |
| Reumuth Mary | A | 11943 | 9525 | 04 янв 2023 г. |
| Trachtenberg Eric | D | 11495 | 60 | 04 янв 2023 г. |
| Trachtenberg Eric | A | 11555 | 9525 | 04 янв 2023 г. |
Новостная лента
KALA Up on Fast Track Designation to Lead Ocular Candidate
Zacks Investment Research
13 апр 2023 г. в 12:56
KALA gets Fast Track Designation from the FDA for lead candidate KPI-012 to treat persistent corneal epithelial defects.
Wall Street Analysts Predict a 213.6% Upside in Kala Pharma (KALA): Here's What You Should Know
Zacks Investment Research
24 мар 2023 г. в 11:27
The mean of analysts' price targets for Kala Pharma (KALA) points to a 213.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
4 Biotech Stocks to Consider for Your Portfolio in 2023
Zacks Investment Research
21 мар 2023 г. в 13:00
New drug approvals and pipeline progress should maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and a solid pipeline progress position CRSP, LGND, THRX and KALA well amid volatility.
Wall Street Bulls Look Optimistic About Kala Pharma (KALA): Should You Buy?
Zacks Investment Research
20 мар 2023 г. в 10:45
The average brokerage recommendation (ABR) for Kala Pharma (KALA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable.
Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
GlobeNewsWire
08 мар 2023 г. в 16:01
ARLINGTON, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye, today announced that it will present at the Oppenheimer 33rd Annual Healthcare Conference. Members of Kala's management team will participate in a virtual fireside chat on Wednesday, March 15, 2023 at 12:00 p.m. ET. Management will also be available for one-on-one meetings on Wednesday, March 15, 2023.